Trial reportAcademic emergency medicine : official journal of the Society for Academic Emergency Medicine2021
Pathway with single-dose long-acting intravenous antibiotic reduces emergency department hospitalizations of patients with skin infections.
Trial report in Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02961764 (A Pragmatic Trial Designed to Evaluate a New Critical Pathway for Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections), which is not on this map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pragmatic Trial Designed to Evaluate a New Critical Pathway for Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
Who cites it
7 citing papers in PubMed, 14 citations in OpenAlex.
- Operationalizing Single-Dose Long-Acting Lipoglycopeptides for Treatment of ABSSSI in a U.S. Community Hospital Emergency Department.Clinical drug investigation · 2026Article
- Clinical outcomes of dalbavancin versus standard therapy for non-severe skin and soft-tissue infections as well as bone and joint infections: a retrospective observational study.JAC-antimicrobial resistance · 2026Article
- Outpatient Parenteral Antimicrobial Therapy in a Setting with High Prevalence of Multidrug Resistance: Challenges, Opportunities, and Stewardship Considerations.Antibiotics (Basel, Switzerland) · 2026Article
- One-Shot, One Opportunity: Retrospective Observational Study on Long-Acting Antibiotics for SSTIs in the Emergency Room-A Real-Life Experience.Pathogens (Basel, Switzerland) · 2025Observational
- The Use of Clinical Pathways in Emergency Departments: A Scoping Review.Health services insights · 2025Review
- Cellulitis: A Review of Current Practice Guidelines and Differentiation from Pseudocellulitis.American journal of clinical dermatology · 2022Review
- The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI.Global & regional health technology assessmentReview
Corrections and comments
- Commented on by
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesEmergency department (ED) patients with serious skin and soft tissue infections (SSTIs) are often hospitalized to receive intravenous (IV) antibiotics. Appropriate patients may avoid admission following a single-dose, long-acting IV antibiotic.
methodsWe conducted a preintervention versus postintervention design trial at 11 U.S. EDs comparing hospitalization rates under usual care to those using a clinical pathway that included a single IV dalbavancin dose. We enrolled adults with cellulitis, abscess, or wound infection with an infected area of ≥75 cm
resultsOf 156 and 153 participants in usual care and clinical pathway periods, median infection areas were 255.0 (interquartile range [IQR] = 150.0 to 500.0) cm
conclusionsImplementation of an ED SSTI clinical pathway for patient selection and follow-up that included use of a single-dose, long-acting IV antibiotic was associated with a significant reduction in hospitalization rate for stable patients with moderately severe infections. Registration: NCT02961764.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.